<DOC>
	<DOC>NCT02712944</DOC>
	<brief_summary>The purpose of this trial is to evaluate the effect of testosterone replacement in men with renal failure (on dialysis) who also have low testosterone. Specifically, the investigators will assess the change in requirement of Erythropoietin Stimulating agents.</brief_summary>
	<brief_title>Testosterone Replacement in Renal Failure</brief_title>
	<detailed_description>Testosterone replacement can increase hemoglobin count. This can therefore decrease the requirement of Erythropoietin Stimulating agents.</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1. Men between ages of 1880 years of age. 2. Renal failure on hemodialysis 3. Free testosterone &lt;5 ng/dl. 4. Willing to be randomized to intramuscular (IM) testosterone or placebo 5. Currently getting intravenous Epoetin alfa 1. Use of testosterone treatment currently or in the past 6 months, including use of over the counter androgen containing health supplements. 2. Congestive heart Failure, class III or IV. 3. Baseline hemoglobin of &gt; 12 g/dl. 4. Allergic reactions to testosterone Vehicle (i.e. Peanut oil) 5. prostate specific antigen&gt;4 ng/ml. 6. History of Prostate Cancer. 7. Liver enzymes &gt;twice the upper limit of normal. 8. HIV or hepatitis C. 9. Severe untreated obstructive sleep apnea (defined as apneahypopnea index&gt; 30). 10. Subjects on warfarin or other blood thinners. 11. Active infection (such as foot ulcer) 12. History of adverse events with testosterone use in past.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>